# 04_QA_REPORT.md

# Quality Assurance Report

## Identity

| Field | Value |
|---|---|
| QA ID | QA-PP-0203 |
| PP ID | PP-0203 |
| Title | Perioperative Chemotherapy |
| Version | 1.0.0 |
| Status | GOLD |
| QA Date | 2026-08-09 |
| Decision Status | Approved / Locked |
| Evidence Basis | Project Source Files |
| Gold Reference | Approved Discussion example + completed Gold 4-MD packages |

---

# QA Purpose

This QA Report verifies that PP-0203:

1. implements the approved and locked Decision Batch;
2. follows the project Gold artifact structure;
3. preserves the required Gold depth;
4. remains grounded in the supplied Source Materials;
5. preserves adjacent PP ownership;
6. provides clinically safe patient-facing education;
7. maintains Knowledge Graph relationships;
8. contains explicit scope and boundary controls;
9. avoids unsupported treatment claims;
10. is complete as a four-artifact Gold package.

---

# Layer 1 — Structural QA

| Criterion | Result | QA Note |
|---|---|---|
| PP identity correct | PASS | PP-0203 — Perioperative Chemotherapy |
| CKO present | PASS | 01_CKO.md |
| Knowledge Passport present | PASS | 02_KNOWLEDGE_PASSPORT.md |
| Primary Evidence Package present | PASS | 03_PRIMARY_EVIDENCE_PACKAGE.md |
| QA Report present | PASS | 04_QA_REPORT.md |
| Four-artifact structure preserved | PASS | No artifact omitted |
| Artifact naming compliant | PASS | Exact standard filenames |
| ZIP packaging | PASS | Single ZIP containing all four artifacts |
| Versioning | PASS | 1.0.0 |
| Title consistency | PASS | PP number/title consistent across artifacts |
| Gold status | PASS | GOLD / READY FOR INTEGRATION |

---

# Layer 2 — Approved Decision Implementation QA

## Locked Decision Coverage

| Locked scope element | Result | Implementation |
|---|---|---|
| Perioperative chemotherapy as strategy | PASS | Core throughout CKO/KP/Evidence |
| Preoperative component | PASS | Dedicated knowledge blocks |
| Postoperative component | PASS | Dedicated knowledge blocks |
| Curative-intent localized/resectable context | PASS | Core scope |
| Surgery remains central | PASS | Explicit |
| Reassessment/restaging | PASS | Explicit |
| MAGIC evidence | PASS | Evidence package + CKO |
| FLOT4 evidence | PASS | Evidence package + CKO |
| FLOT as regimen example | PASS | Introduced without consuming PP-0204 |
| Perioperative vs adjuvant | PASS | Dedicated distinction |
| Perioperative vs neoadjuvant | PASS | Dedicated distinction |
| Chemotherapy vs chemoradiation | PASS | Explicit boundary |
| Curative vs palliative | PASS | Explicit boundary |
| Pathology/postoperative interface | PASS | Explicit |
| Lymphadenectomy interface | PASS | Explicit |
| Treatment completion | PASS | Explicit |
| High-level toxicity | PASS | Explicit |
| Biomarker context | PASS | Supporting only |
| Immunotherapy evolution | PASS | Supporting only |
| Patient questions | PASS | Dedicated sections |
| Misconceptions | PASS | Dedicated section |
| Boundary | PASS | Core/Supporting/Excluded/Delegated |

---

# Layer 3 — Source Fidelity QA

## Source-First Verification

The project Source Files were searched before production.

Relevant sources identified:

- NCCN Gastric Cancer v2.2026;
- NCI Gastric Cancer Treatment PDQ;
- ACS Chemotherapy for Stomach Cancer;
- ESMO-ASCO Global Curriculum 2023;
- project Discussion depth/format example;
- completed Gold artifact references;
- governance source files.

**Result: PASS**

---

# Source Hierarchy QA

## NCCN

Used for:

- current guideline framework;
- perioperative systemic therapy;
- FLOT positioning;
- postoperative treatment context;
- surgery/pathology interfaces;
- biomarker-related treatment context.

**Result: PASS**

---

## NCI

Used for:

- MAGIC;
- FLOT4;
- survival outcomes;
- margin-free resection;
- toxicity patterns;
- treatment context.

**Result: PASS**

---

## ACS

Used for:

- patient-facing chemotherapy explanation;
- treatment timing concepts;
- patient-facing terminology.

**Result: PASS**

---

## ESMO-ASCO

Used for:

- multidisciplinary treatment;
- treatment sequencing;
- functional status;
- biomarker context;
- perioperative/adjuvant treatment concepts.

**Result: PASS**

---

# Evidence Traceability QA

## Major Claims

### Claim 1

Perioperative chemotherapy is a recognized strategy around surgery.

**Source:** NCCN v2.2026; NCI PDQ.

**Result:** PASS.

---

### Claim 2

MAGIC demonstrated improved PFS and OS with perioperative chemotherapy compared with surgery alone.

**Source:** NCI Gastric Cancer Treatment PDQ.

**Result:** PASS.

---

### Claim 3

MAGIC reported 5-year OS of 36.3% versus 23%.

**Source:** NCI Gastric Cancer Treatment PDQ.

**Result:** PASS.

---

### Claim 4

FLOT4 included 716 patients with stage IB–III resectable gastric/GEJ adenocarcinoma.

**Source:** NCI Gastric Cancer Treatment PDQ.

**Result:** PASS.

---

### Claim 5

FLOT4 reported median OS 50 versus 35 months.

**Source:** NCI Gastric Cancer Treatment PDQ.

**Result:** PASS.

---

### Claim 6

FLOT4 reported HR 0.77 for death.

**Source:** NCI Gastric Cancer Treatment PDQ.

**Result:** PASS.

---

### Claim 7

FLOT4 reported margin-free resection 85% versus 78%.

**Source:** NCI Gastric Cancer Treatment PDQ.

**Result:** PASS.

---

### Claim 8

FLOT and ECF/ECX had different toxicity patterns.

**Source:** NCI Gastric Cancer Treatment PDQ.

**Result:** PASS.

---

### Claim 9

Postoperative management incorporates pathologic and surgical findings.

**Source:** NCCN v2.2026.

**Result:** PASS.

---

### Claim 10

Treatment sequencing is multidisciplinary and influenced by stage, functional status, and biomarkers.

**Source:** ESMO-ASCO 2023; NCCN.

**Result:** PASS.

---

# Clinical Safety QA

| Safety Criterion | Result | QA Note |
|---|---|---|
| No individualized treatment recommendation | PASS | Strategy education only |
| No individualized FLOT recommendation | PASS | FLOT delegated |
| No dosing | PASS | Excluded |
| No cycle prescription | PASS | Excluded |
| No dose modification | PASS | Excluded |
| No administration instructions | PASS | Excluded |
| No metastatic treatment algorithm | PASS | Delegated to PP-0208 |
| No immunotherapy algorithm | PASS | Delegated |
| No targeted-therapy algorithm | PASS | Delegated |
| No surgical technique | PASS | Delegated |
| No D1/D2 technique | PASS | Delegated |
| No individualized pathology interpretation | PASS | Interface only |
| No guarantee of cure | PASS | Curative intent explicitly distinguished from cure |
| No universal stage-only rule | PASS | Selection is multifactorial |
| No claim that every patient receives FLOT | PASS | Explicitly avoided |
| Treatment completion uncertainty preserved | PASS | Explicit |
| Toxicity uncertainty preserved | PASS | Explicit |

---

# Patient-Facing QA

| Criterion | Result | QA Note |
|---|---|---|
| Plain language | PASS | Technical terms explained |
| Patient-facing questions | PASS | Before and after surgery |
| Common misconceptions | PASS | Dedicated section |
| Clear treatment sequence | PASS | Dedicated knowledge block |
| Strategy/regimen distinction | PASS | Explicit |
| Perioperative/adjuvant distinction | PASS | Explicit |
| Perioperative/neoadjuvant distinction | PASS | Explicit |
| Chemotherapy/chemoradiation distinction | PASS | Explicit |
| Curative/palliative distinction | PASS | Explicit |
| Appropriate uncertainty | PASS | No overclaim |
| Clinician discussion encouraged | PASS | Repeatedly embedded |
| No false reassurance | PASS | Treatment limitations described |
| No unnecessary technical detail | PASS | Detailed downstream topics delegated |

---

# Evidence Interpretation QA

## Established / Guideline-Supported

PASS:

- perioperative systemic treatment framework;
- FLOT preferred role in relevant current guideline context;
- surgical integration;
- postoperative decision interface.

## Randomized Evidence

PASS:

- MAGIC;
- FLOT4;
- selected numerical outcomes.

## Context-Dependent

PASS:

- regimen choice;
- treatment fitness;
- postoperative completion;
- biomarker-defined options;
- evolving perioperative immunotherapy.

## Unsupported Claims Avoided

PASS:

- no universal regimen;
- no universal cycle number;
- no universal stage-only rule;
- no guaranteed cure;
- no universal toxicity prediction.

---

# Adjacent PP Boundary QA

## PP-0196 — Gastrectomy Principles

No substantive duplication.

**PASS**

---

## PP-0197 — Subtotal Gastrectomy

No substantive duplication.

**PASS**

---

## PP-0198 — Total Gastrectomy

No substantive duplication.

**PASS**

---

## PP-0199 — Lymphadenectomy

Only postoperative interface retained.

**PASS**

---

## PP-0200 — D1 Lymphadenectomy

Only postoperative interface retained.

**PASS**

---

## PP-0201 — D2 Lymphadenectomy

Only postoperative interface retained.

**PASS**

---

## PP-0202 — Sentinel Lymph Node

No substantive duplication.

**PASS**

---

## PP-0204 — FLOT

FLOT introduced as regimen example but detailed ownership delegated.

**PASS**

---

## PP-0205 — Adjuvant Therapy

Terminology and postoperative interface only.

**PASS**

---

## PP-0206 — Neoadjuvant Therapy

Preoperative component introduced but detailed ownership delegated.

**PASS**

---

## PP-0207 — Chemoradiation

Contrast only.

**PASS**

---

## PP-0208 — Palliative Systemic Therapy

Curative-intent boundary preserved.

**PASS**

---

## PP-0209–0212 — Targeted Therapy

Biomarker/systemic-treatment context only.

**PASS**

---

## PP-0213–0216 — Immunotherapy

Evolution/context only.

**PASS**

---

# Knowledge Graph QA

## Prerequisite Links

PASS:

- staging;
- treatment overview;
- surgery;
- lymphadenectomy.

## Related Links

PASS:

- gastrectomy;
- lymphadenectomy;
- sentinel lymph node;
- chemoradiation;
- multidisciplinary treatment.

## Downstream Links

PASS:

- FLOT;
- adjuvant;
- neoadjuvant;
- chemoradiation;
- palliative;
- targeted therapy;
- immunotherapy.

---

# Gold Depth QA

## Gold Rule

The project Source Files state that approved Gold references establish the **minimum expected depth** and that artifacts must not be compacted, shortened, summarized, or reduced in reasoning, evidence, QA, Knowledge Graph, or patient-facing depth.

This package follows that requirement.

**Result: PASS**

---

# Gold Structure QA

## 01_CKO.md

Required elements present:

- metadata;
- educational objectives;
- primary question;
- scope;
- included;
- excluded;
- knowledge blocks;
- patient explanation;
- clinical importance;
- key concepts;
- misconceptions;
- key messages;
- Knowledge Graph;
- boundary;
- revision history.

**PASS**

---

## 02_KNOWLEDGE_PASSPORT.md

Required elements present:

- identity;
- classification;
- atomic question;
- patient journey;
- runtime usage;
- retrieval terms;
- clinical scope;
- source set;
- evidence classification;
- evidence boundaries;
- Knowledge Graph;
- runtime logic;
- safety rules;
- governance metadata;
- version control.

**PASS**

---

## 03_PRIMARY_EVIDENCE_PACKAGE.md

Required elements present:

- identity;
- clinical question;
- scope;
- primary sources;
- evidence hierarchy;
- evidence matrix;
- detailed evidence notes;
- evidence gaps;
- delegation matrix;
- evidence consistency;
- traceability;
- boundary verification;
- Knowledge Graph verification;
- safety principles;
- final evidence position;
- version history.

**PASS**

---

## 04_QA_REPORT.md

Required layers present:

1. Structural QA.
2. Approved Decision Implementation QA.
3. Source Fidelity QA.
4. Source Hierarchy QA.
5. Evidence Traceability QA.
6. Clinical Safety QA.
7. Patient-Facing QA.
8. Evidence Interpretation QA.
9. Adjacent PP Boundary QA.
10. Knowledge Graph QA.
11. Gold Depth QA.
12. Gold Structure QA.
13. Final Quality Decision.

**PASS**

---

# Boundary QA

Required four-part structure preserved:

### Core

Perioperative chemotherapy strategy and its clinical sequence.

### Supporting

Selected evidence and clinical interfaces.

### Explicitly Excluded

Detailed downstream modality/regimen content.

### Delegated-to PP

Explicit downstream ownership.

**Result: PASS**

---

# Governance QA

| Governance Requirement | Result |
|---|---|
| Source-First | PASS |
| User-controlled PP sequence | PASS |
| Approved Decision Batch implemented | PASS |
| Immediate Gold production | PASS |
| Four artifacts | PASS |
| ZIP package | PASS |
| Gold depth preserved | PASS |
| Adjacent PP overlap checked | PASS |
| Boundary declared | PASS |
| No scope reopening | PASS |
| No unsupported external evidence | PASS |
| Stop after completion | PASS |

---

# Package Completeness

| Artifact | Present | QA |
|---|---|---|
| 01_CKO.md | YES | PASS |
| 02_KNOWLEDGE_PASSPORT.md | YES | PASS |
| 03_PRIMARY_EVIDENCE_PACKAGE.md | YES | PASS |
| 04_QA_REPORT.md | YES | PASS |

ZIP structure:

```text
PP-0203_Perioperative_Chemotherapy_GOLD_v1.0.0/
├── 01_CKO.md
├── 02_KNOWLEDGE_PASSPORT.md
├── 03_PRIMARY_EVIDENCE_PACKAGE.md
└── 04_QA_REPORT.md
```

---

# Final Quality Decision

# PASS

PP-0203 satisfies the approved/locked Decision Batch and the project Gold Population Package production standard.

The package maintains the intended architecture:

**Localized / Resectable Gastric Cancer**

↓

**Curative-Intent Multimodality Treatment**

↓

**PP-0203 — Perioperative Chemotherapy**

↓

**Preoperative Systemic Therapy**

↓

**Reassessment**

↓

**Surgery**

↓

**Pathology**

↓

**Postoperative Systemic Therapy**

↓

**Downstream Specialized Treatment Packages**

The package does not duplicate the substantive ownership of:

- gastrectomy;
- lymphadenectomy;
- FLOT;
- adjuvant therapy;
- neoadjuvant therapy;
- chemoradiation;
- palliative systemic therapy;
- targeted therapy;
- immunotherapy;
- detailed biomarker testing;
- detailed toxicity management.

---

# Reviewer Notes

PP-0203 functions as a **treatment-strategy bridge node**.

Its main value is not to add another generic chemotherapy package.

Its value is to explain the clinical relationship:

**systemic therapy**

↔

**surgery**

and why treatment is intentionally distributed across the perioperative period.

The package deliberately preserves several important distinctions:

1. **Strategy ≠ regimen.**
2. **Perioperative ≠ adjuvant.**
3. **Perioperative ≠ neoadjuvant.**
4. **Chemotherapy ≠ chemoradiation.**
5. **Curative intent ≠ guaranteed cure.**
6. **Planned treatment ≠ necessarily delivered treatment.**
7. **Biomarker information ≠ automatic treatment selection.**

These safeguards are central to the Gold educational boundary.

---

# Final Status

**QA final status: PASS — GOLD — READY FOR INTEGRATION.**
